JPRN-UMIN000032600已完成未知
EFFICACY AND SAFETY OF NIVOLUMAB IN RECURRENT OR METASTATIC HEAD AND NECK CANCER (HNC) PATIENTS - JAPANESE REAL-WORLD DATA THROUGH CLINICAL CHART REVIEW - - - JAPANESE REAL-WORLD DATA THROUGH CLINICAL CHART REVIEW
Bristol-Myers Squibb Ono Pharmaceutical CO.,LTD.0 个研究点目标入组 256 人开始时间: 2018年5月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 256
研究概览
简要总结
Refer to the following articles Int J Clin Oncol. 2021 Mar;26(3):494-506. Int J Clin Oncol. 2021 Jun;26(6):1049-1056. Int J Clin Oncol. 2022 Jan;27(1):95-104.
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •History of participation in any clinical trials prior- or post-nivolumab treatment
研究者
相似试验
已完成
3 期
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerVarious Advanced CancerNCT02632409Bristol-Myers Squibb709
已完成
不适用
Clinical trial of nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck cancer after six months who finished platinum-based chemotherapyHead and Neck squamous cell carcinomaJPRN-UMIN000031324Tokyo Medical University50
招募中
2 期
Pan Tumor Rollover StudyCancerNCT03899155Bristol-Myers Squibb1,500
已完成
2 期
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)Hodgkin DiseaseNCT02181738Bristol-Myers Squibb294
已完成
3 期
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal CancerEsophageal CancerNCT02569242Ono Pharmaceutical Co. Ltd419